Nkarta, Inc.
$3.49
▲
5.94%
2026-04-21 08:25:01
www.nkartatx.com
NMS: NKTX
Explore Nkarta, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$247.38 M
Current Price
$3.49
52W High / Low
$3.48 / $1.63
Stock P/E
—
Book Value
$4.39
Dividend Yield
—
ROCE
-31.94%
ROE
-28.9%
Face Value
—
EPS
$-1.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
108
Beta
0.67
Debt / Equity
24.47
Current Ratio
12.69
Quick Ratio
12.69
Forward P/E
-1.21
Price / Sales
—
Enterprise Value
$-45.16 M
EV / EBITDA
0.42
EV / Revenue
—
Rating
None
Target Price
$14.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Neurogene Inc. | $27.74 | — | $432.03 M | — | -37.96% | -31.41% | $37.27 / $10.46 | $17.1 |
| 2. | 4D Molecular Therapeutics, Inc. | $10.07 | — | $535.53 M | — | -30.52% | -27.57% | $12.34 / $2.88 | $8.78 |
| 3. | Bone Biologics Corporation | $1.38 | — | $2.5 M | — | -60.16% | -70.17% | $6.75 / $1.05 | $3 |
| 4. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
| 5. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 6. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 7. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -30.96 M | -27.29 M | -27.19 M | -36.56 M | -30.92 M | — |
| Net Profit | -27.41 M | -21.71 M | -22.98 M | -31.98 M | -25.93 M | — |
| EPS in Rs | -0.38 | -0.3 | -0.32 | -0.45 | -0.36 | -0.39 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -122 M | -128.19 M | -131.65 M | -118.95 M |
| Net Profit | -104.08 M | -108.79 M | -117.5 M | -113.84 M |
| EPS in Rs | -1.46 | -1.53 | -1.65 | -1.6 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 404.21 M | 501.2 M | 378.88 M | 472.94 M |
| Total Liabilities | 91.88 M | 93.23 M | 105.6 M | 100.73 M |
| Equity | 312.32 M | 407.98 M | 273.29 M | 372.21 M |
| Current Assets | 282.51 M | 273.34 M | 253.07 M | 360.69 M |
| Current Liabilities | 22.27 M | 18.92 M | 23.33 M | 22.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -88.7 M | -99.7 M | -86.16 M | -57 M |
| Investing CF | 100.32 M | -129.56 M | 79.02 M | -184.69 M |
| Financing CF | 0.14 M | 226.08 M | 0.69 M | 219.01 M |
| Free CF | -89.91 M | -104.11 M | -114.31 M | -104.11 M |
| Capex | -1.21 M | -4.41 M | -28.15 M | -47.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 4.33% | 7.41% | -3.22% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.